Case Study:
Influenza A – H1N1 vaccinal preparation

Influenza A viruses cause major morbidity and represent a severe human health threat. Current influenza vaccines are mainly egg-based products requiring the split of whole viruses using classical detergents such as Triton X-100 with several limitations and drawbacks.

Here, we report the use of the novel calixarene-based detergent CALX133ACE as an alternative to the classical surfactants for influenza inactivated vaccine preparation.

We confirmed that CALX133ACE-based split HA antigens are fully functional and quantifiable by the “gold standard” method SRID.

Additionally, CALX133ACE-based split antigens were stable for at least 2 years at 4°C and at least as thermostable as Triton X-100-based split.

Immunization of mice with CALX133ACE-based split NYMC X-179A (H1N1) antigens harboring 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip® or Fluviral® induced comparable protection and neutralizing antibody responses against A(H1N1)pdm09 infection.

Taken together, our results demonstrated for the first time the use of a calixarene-based detergent as efficient splitting agent for the production of optimized influenza split antigens, paving the way for significant improvement of the vaccine manufacturing process, notably with regard to the current regulation on the prohibition of endocrine disruptors, such as Triton X-100.


For licensing opportunities, contact us here.



Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection

Mandon E et al. 2020


Novel influenza vaccine : Calixar patent granted in Europe

Mandon E et al, 2020 January – Small summary of the article, findings and usages.